• Link to Facebook
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Link to Bluesky Link to BlueskyLink to Bluesky
  • Link to Instagram
  • ESO
  • ESOC 2026
  • ESOC 2027
  • STROKE INSIGHTS
  • eSTEP
  • MEMBERSHIP
  • SUPPORT US
THE VOICE OF STROKE IN EUROPE
European Stroke Organisation
  • About
    • What we do
    • Who we are
      • Leadership
      • ESO Committees
      • Honorary Members
      • Award Recipients & Awards Selection Committee
      • Young Stroke Physicians and Researchers Committee
      • DEI Advisory Council
      • Head Office
    • Membership
      • Benefits
      • Individual Membership
      • Organisational Membership
      • Membership Fees
    • Governance
      • Bylaws and Statues, Advocacy
      • Code of Conduct
    • History
    • Global Stroke Cooperation
  • Meetings
    • ESO Conference
    • ICH Academy Meeting (IAM)
    • Simulation Workshop 2026
    • Winter School
    • Summer School
    • Edinburgh Stroke Research Workshop
    • European Stroke Science Workshop
    • Focused Workshop
    • Educational Webinars
    • ESO Endorsed Meetings and Education
      • Applications for Endorsement
    • Events Calendar
  • Guidelines
    • ESO Guideline Directory
    • ESO Guideline Board
    • ESO Guideline Development Webinar
  • Projects
    • ANGELS
    • ESO EAST (Enhancing and Accelerating Stroke Treatment)
    • RES-Q — Registry of Stroke Care Quality
    • EU Research Partnerships
    • QASC
    • Stroke Action Plan for Europe (SAP-E)
    • Stroke Unit and Stroke Centre Certification
    • WISE
  • Resources
    • eSTEP
    • Emerging Leader Programme
    • European Master Programme in Stroke Medicine
    • Department to Department Visit Programme
    • ESO Trials Alliance
    • European Telestroke Networks
    • COVID-19 Resources
    • Task Force 4 Ukraine
  • News and Media
    • European Stroke Journal (ESJ)
    • Blog
    • Podcast
    • Paper of the Month
    • Press
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Capsular Warning Syndrome: not all TIAs remain the same

Giuseppe Reale, MD1,2; Marco Moci, MD2.

1Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neuroriabilitazione ad Alta Intensità

2Università Cattolica del Sacro Cuore – Roma, Dipartimento di Neuroscienze

Transient Ischemic Attack (TIA) is usually characterized by transient focal neurological signs such as speech disturbances, hemiparesis or partial visual loss, without any neuroimaging evidence of cerebral ischemia1,2. Short-term risk of stroke after TIA is high: according to the most used score for assessing such risk, ABCD2 score, the risk of stroke within the first 48 hours ranges from 1% to 8.1%, depending on symptoms, their duration, patients’ age, hypertension and diabetes3. However, not all focal neurological signs are the same. This is the case of Capsular Warning Syndrome (CWS) that constitutes a subgroup of all TIAs. First described by Donnan et al in 1993, CWS consists of acute, transient, stereotypical sensory and/or motor symptoms affecting the face, arm and/or leg. There has to be an absence of cortical signs and it has to occur within a seven-day period after an index TIA4–6.

The most comomn manifestation of CWS is with a pure hemiparesis, the number of episodes mostly ranging between 3 to 10 (even in a single day), their mean duration being about 6 minutes, and appearing in “clusters”4–6. Although CWS is only responsible of 1.5-4.5% of all TIAs, the risk of ischemic stroke is likely high, with an incidence ranging between 17% and 70%. A recent review even showed that 74% of these patients had infarction on neuroimaging, which is far above the 8% risk detectable with ABCD2  score4–6. The ABCD3-I score proposed in 2010 added occurrence of at least two TIAs – a so called ‘dual TIA’ – to the stroke risk score7–9 and this was later validated in a Chinese population. However, when the recurrences of symptoms in a patients with a CWS is regarded as a ‘dual TIAs’, the risk of subsequent stroke is likely underestimated10. Pathophysiological mechanisms that might explain such increased risk of ischemic stroke are still unclear. Several mechanisms might contribute to the ischemic damage, including penetrating small vessel disease, hemodynamic impairment, branch-artery disease, artery-to-artery embolism and peri-infarct depolarization6.

Regarding treatment, dual antiplatelet therapy is the mainstay for all TIAs, CWS included6,11,12. Other potential therapies are matter of investigation, such as intravenous tirofiban (overlap loading Clopidogrel 300 mg and Aspirin 100 mg), which has been suggested as a potential intervention toreduce fluctuations in CWS patients13. When a DWI-FLAIR mismatch on MRI in the acute symptomatic phase is present, choosing thrombolytic therapy is reasonable.

In conclusion, CWS represent a non-neglectable sub-group of TIAs, it is characterized by several episodes of transient subcortical neurological symptoms and has a high risk of stroke progression. Therefore, when evaluating a TIA, suspecting CWS could have a significant impact on patients’ management strategies, especially in terms of monitoring during the early stage.

REFERENCES

  1. Sorensen AG, Ay H. Transient ischemic attack: definition, diagnosis, and risk stratification. Neuroimaging Clin N Am. 2011;21:303–313, x.
  2. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276–2293.
  3. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–292.
  4. Paul NLM, Simoni M, Chandratheva A, Rothwell PM. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology. 2012;79:1356–1362.
  5. Donnan GA, O’Malley HM, Quang L, Hurley S, Bladin PF. The capsular warning syndrome: pathogenesis and clinical features. Neurology. 1993;43:957–962.
  6. Sales C, Calma AD. Stroke warning syndrome. Clinical Neurology and Neurosurgery. 2022;213:107120.
  7. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Furie KL, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol. 2010;9:1060–1069.
  8. Knoflach M, Lang W, Seyfang L, Fertl E, Oberndorfer S, Daniel G, Seifert-Held T, Brainin M, Krebs S, Matosevic B, et al. Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. Neurology. 2016;87:861–869.
  9. Kiyohara T, Kamouchi M, Kumai Y, Ninomiya T, Hata J, Yoshimura S, Ago T, Okada Y, Kitazono T, Fukuoka Stroke Registry Investigators. ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke. 2014;45:418–425.
  10. Song B, Fang H, Zhao L, Gao Y, Tan S, Lu J, Sun S, Chandra A, Wang R, Xu Y. Validation of the ABCD3-I Score to Predict Stroke Risk After Transient Ischemic Attack. Stroke. 2013;44:1244–1248.
  11. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N. Engl. J. Med. 2018;379:215–225.
  12. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. N Engl J Med. 2013;369:11–19.
  13. Li W, Wu Y, Li X-S, Liu C-C, Huang S-H, Liang C-R, Wang H, Zhang L-L, Xu Z-Q, Wang Y-J, et al. Intravenous tirofiban therapy for patients with capsular warning syndrome. Stroke Vasc Neurol. 2019;4:22–27.

Recent Posts

  • Functional outcomes and quality of life after endovascular thrombectomy in large and extensive infarcts (ASPECTS 0–5): a multicentre registry study 13/11/2026
  • D2D Report – Michael Yirgalem Teka 06/11/2026
  • Train the Trainer workshop: learning to build our own stroke simulations 30/10/2026
  • Highlights from the 10th World Intracranial Hemorrhage Conference 23/10/2026
  • Beyond angiography: flat-panel imaging after thrombectomy 16/10/2026
  • D2D Report – Dimitar Mitsev 09/10/2026
  • The Expanding Role of Endovascular Therapy in Cerebral Venous Sinus Thrombosis 02/10/2026
  • ESJ Featured Article of the Month – September 2026: Anaesthesia during medium and distal vessel thrombectomy: a signal, not yet a strategy 25/09/2026
  • ESO TF4UKR D2D Report – Alina Trubetska 18/09/2026
  • Post-Stroke Complications 11/09/2026

Tags

2021 acute ischemic stroke brain cardiology career clinical D2D department to department visit emergency medicine ESJ ESO ESO-EAST ESOC ESOC 2018 ESOC 2019 ESOC 2022 ESOC 2023 ESOC 2024 ESOC 2025 ESOWSO2020 Europe European Stroke Journal FESO guidelines hospital interview ischaemic stroke ischemic stroke networking Neurology newsletter research SAFE stroke stroke care Stroke Center stroke in the young stroke research stroke treatment stroke trials TF4UKR TIA trials virtual YSPR

Archive

Categories

  • ESO
  • ESOC
  • IRT Post
  • Stroke Research

European Stroke Organisation
Reinacherstrasse 131
4053 Basel / Switzerland
E: esoinfo@eso-stroke.org

  • Home
  • ESO Conference
  • Blog
  • My ESO
  • Membership
  • Subscribe to our Newsletter
© ESO-STROKE 2024 — the Voice of Stroke in Europe
  • Link to Facebook
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Link to Bluesky Link to BlueskyLink to Bluesky
  • Link to Instagram
  • Imprint
  • Privacy Statement
  • Disclaimer
  • Contact
Scroll to top Scroll to top Scroll to top